Tabernanthe iboga
Viewing r2 — May 14, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
''Iboga (Tabernanthe iboga'' Baillon, Apocynaceae) — eboka — is a West and Central African rainforest shrub whose root bark is consumed as a powerful psychoactive preparation. Its principal alkaloid, ibogaine, is a pentacyclic monoterpene indole alkaloid with an exceptionally broad multi-target receptor profile.[1] Ibogaine produces its effects through simultaneous action on NMDA, kappa opioid, nicotinic, and serotonin systems, generating prolonged visionary and dissociative states.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Formally described in 1888,[2] T. iboga is the sacramental plant of the Bwiti religion in Gabon.[3] Western addiction-treatment interest began in 1962 when Howard Lotsof reported cessation of opioid withdrawal after self-administration,[4] and the 2024 MISTIC trial demonstrated large effect sizes for PTSD and traumatic brain injury.[5] A 2026 US executive order directed accelerated regulatory review,[6] though ibogaine remains Schedule I at the federal level.
Subjective effects include narrative autobiographical visions, dissociative states, entity-contact phenomena, somatosensory hypersensitivity, and severe ataxia.[7] The experience is predominantly internal and oneirophrenic, lasting 12–24 hours in acute phase with residual effects persisting up to 72 hours due to noribogaine's prolonged half-life.[8] Near-universal physical incapacitation, intense nausea, and confrontation with difficult psychological material are characteristic unsought effects.[9]
Ibogaine does not produce physical dependence, tolerance, or compulsive redosing.[10] The primary safety concern is cardiac: ibogaine and noribogaine block the hERG potassium channel, producing QTc prolongation that has caused fatal arrhythmias in unsupervised settings.[11] No controlled dose-response data from randomized trials have been published, and root bark preparations carry additional risk from extreme alkaloid concentration variability (0.6–11.2% ibogaine content).[12]
History[edit]
Traditional and historical use
Tabernanthe iboga was formally described by Henri Ernest Baillon in 1888.[2] French colonial botanists had encountered the plant in Gabon during the preceding decades, and specimens reached European herbaria before the formal publication.
The plant is the sacramental core of the Bwiti religion, practiced primarily by the Mitsogho, Fang, and Babongo peoples of Gabon and neighboring countries.[3] Iboga root bark is consumed in two principal traditional contexts.[13][3] Large initiation doses are administered over one to three days, producing prolonged visionary states understood as symbolic death-and-rebirth experiences enabling contact with ancestral spirits. Smaller ceremonial doses are taken for healing, guidance, or communal purposes without reaching the full visionary threshold. Sub-visionary doses are also used to combat fatigue during extended hunting, treat fever and pain, and as an aphrodisiac.[13]
No controlled ethnopharmacological studies with quantified alkaloid dosing have been conducted in the traditional Bwiti setting.
Western discovery and research
The first alkaloid isolation from T. iboga root bark is attributed to Dybowsky and Landrin in 1901.citation needed The structural chemistry of the four major alkaloids — ibogamine, ibogaine, tabernanthine, and voacangine — was established by Bartlett, Dickel, and Taylor in 1958.[14]
In the 1930s–1950s, ibogaine was marketed in France as "Lambarene" (5 mg tablets), prescribed as a fatigue remedy and mild stimulant.citation needed In 1962, Howard Lotsof, a 19-year-old heroin-dependent American, self-administered ibogaine and reported cessation of opioid craving and withdrawal.[4] He subsequently obtained US patents for ibogaine treatment of multiple substance dependencies. The DEA classified ibogaine as Schedule I in 1967,citation needed and in the 1990s Mash et al. initiated Phase I clinical trials at a clinic in St. Kitts, outside US jurisdiction.[15][16]
Modern era
Gabon declared T. iboga a "national cultural heritage strategic reserve" in 2000 and enacted an export ban on wild-harvested iboga in 2019.[17] The 2024 MISTIC trial at Stanford reported large effect sizes for PTSD (Cohen's d = 2.54), depression (d = 2.80), and anxiety (d = 2.13) in 30 special operations veterans with traumatic brain injury following a magnesium-ibogaine protocol.[5]
A 2026 US executive order directed the FDA and DEA to accelerate ibogaine research and create Right to Try access pathways.[6] As of May 2026, nine US states have enacted ibogaine-related legislation, primarily funding clinical research programs.[18]
Botanical Overview[edit]
Tabernanthe iboga Baillon belongs to the family Apocynaceae (dogbane family), a large family of tropical and subtropical flowering plants that also includes oleander, periwinkle, and several other alkaloid-producing genera. The genus Tabernanthe is small, containing only a handful of recognized species, of which T. iboga is by far the most pharmacologically significant.
The plant is native to the rainforest understory of West and Central Africa, occurring naturally in Gabon, Cameroon, the Republic of Congo, and the Democratic Republic of Congo. It thrives in the shaded, humid conditions beneath the tropical lowland forest canopy. Wild populations face increasing harvest pressure; Gabon enacted an export ban on wild-harvested material in 2019, though cultivation is permitted with Ministry approval.[17] The plant grows slowly, typically requiring several years before root bark accumulates harvestable alkaloid concentrations.
T. iboga is a small evergreen perennial shrub, typically reaching 1.5–2 metres in height under forest conditions. It produces glossy, dark green opposite leaves with prominent midribs. Small white or pinkish tubular flowers develop into oval orange-yellow fruits. The root system is the pharmacologically important structure — psychoactive alkaloids are concentrated in the root bark, with the inner root bark containing the highest concentrations. Stem bark and leaves contain alkaloids at substantially lower levels.
Root bark is traditionally harvested by scraping or shaving the inner bark from excavated roots, which is then dried for ceremonial and medicinal use. Because the root system is the harvested part, destructive harvesting kills or severely damages the parent plant — a key factor in wild population decline and the impetus for Gabon's conservation protections.
Alkaloid Profile[edit]
Dominant alkaloid: ibogaine
Ibogaine is a pentacyclic monoterpene indole alkaloid and the primary psychoactive constituent of T. iboga root bark. Concentrations in root bark vary enormously — from 0.6% to 11.2% of dry weight across samples[12] — making dose prediction from uncharacterized plant material unreliable. Ibogaine engages an unusually broad set of receptor targets simultaneously, a profile described as "matrix pharmacology"[1]: NMDA antagonism, kappa opioid receptor agonism, nicotinic α3β4 receptor antagonism,[19] SERT inhibition, and VMAT2 (VMAT2) inhibition.[1]
Noribogaine: the sustained metabolite
CYP2D6-mediated metabolism converts ibogaine to noribogaine, its primary active metabolite. Noribogaine shares many of ibogaine's receptor targets — including VMAT2 inhibition, serotonin transporter inhibition, and kappa opioid agonism[1][20] — but its half-life of 28–48 hours far exceeds ibogaine's 7–10 hours.[8] This prolonged presence sustains serotonergic and kappa opioid activity well beyond the acute visionary phase and extends the window of cardiac risk.
Minor alkaloids
Root bark contains several additional indole alkaloids, including tabernanthine, ibogamine, and voacangine. Voacangine is notable for its hERG channel blockade potency.[21] Whether these minor co-alkaloids contribute meaningfully to therapeutic or adverse effects at human exposure concentrations has not been determined. Their presence distinguishes the pharmacology of whole root bark from that of purified ibogaine HCl.
Concentration variability
Alkaloid concentrations in T. iboga root bark vary dramatically across individual plants, growing conditions, plant age, and the specific root section harvested. GC/MS analysis of commercial iboga products found unknown substances in almost all samples tested, and one product labeled as "iboga" contained no detectable iboga alkaloids.[12] This variability makes standardized dosing from raw root bark impossible without analytical verification.
Neuroscience[edit]
Where it acts
Ibogaine's broad receptor profile produces a convergent assault on multiple neurotransmitter systems. It simultaneously modulates serotonin release and reuptake through a dual mechanism — inhibiting both VMAT2 (the vesicular transporter) and SERT (the plasma membrane transporter) — a pattern termed "SynRI".[1] At the same time, it blocks NMDA glutamate receptors,[22] activates kappa opioid receptors,[20] antagonizes nicotinic α3β4 receptors,[19] and functions as a biased partial agonist at mu-opioid receptors.[23] 5-HT₂A receptor involvement is supported by knockout mouse studies.[24] Noribogaine sustains much of this activity over its 28–48-hour half-life.[8]
What it changes
The anti-addictive potential of ibogaine appears to arise from several converging mechanisms[20][25]: acute suppression of dopamine in the nucleus accumbens reduces drug-reward reinforcement; upregulation of glial cell line-derived neurotrophic factor (GDNF) in the ventral tegmental area reduces alcohol self-administration in animal models;[26] and NMDA antagonism attenuates opioid and stimulant withdrawal through glutamatergic normalization.[20][22] Structural brain changes in the MISTIC cohort at one month post-treatment included increased cortical thickness in 11 regions, subcortical expansion in 8 regions, and a 1.3-year reduction in estimated brain age.[27]
The relative contribution of ibogaine versus noribogaine to anti-addictive efficacy remains unresolved — the two compounds have overlapping but distinct receptor profiles and strikingly different durations of action. Whether the minor co-alkaloids in root bark meaningfully alter the therapeutic or adverse effect profile at human doses is unknown. Long-term Purkinje cell effects in humans at therapeutic doses remain uncharacterized, and the remyelination hypothesis[25] awaits direct human evidence.
Subjective Effects[edit]
The ibogaine experience is qualitatively unlike either classical serotonergic psychedelics or dissociative anesthetics, though it shares features with both. Root bark and purified ibogaine HCl both produce an extended, largely internal visionary state dominated by narrative autobiographical sequences, entity encounters, and intense somatic load.[7] The experience is heavily dose-dependent and preparation-dependent: raw root bark delivers the full alkaloid spectrum at unpredictable concentrations, potentially shifting both character and duration compared to pharmaceutical-grade ibogaine HCl. Set, setting, and intention strongly modulate the psychological content, though the physical intensity — severe ataxia, nausea, sensitivity to sound and light — is largely invariant above threshold doses.[9]
Ibogaine occupies a singular position among psychoactive plants. Its closest pharmacological parallels are synthetic analogs (tabernanthalog, oxa-noribogaine) rather than other botanical preparations. The 12–24-hour acute duration, residual effects persisting to 72 hours, severe physical incapacitation, and mandatory cardiac monitoring requirements distinguish it from all commonly discussed psychedelic or dissociative substances.
Effect Grid
The therapeutic anti-addictive range at 10–20 mg/kg ibogaine HCl produces the full ibogaine experience. Internal hallucinations dominate: extended autobiographical narrative sequences, memory replays, entity contact, and transpersonal visions unfold over hours. Introspection enhancement is intense, with deep self-examination and catharsis frequently reported. Anxiety and dysphoria co-occur alongside cognitive euphoria and emotional enhancement. Reality testing impairment is significant — subjects are largely immobilized and non-communicative during the peak.
Severe motor control impairment (ataxia) occurs in nearly all subjects. Nausea and vomiting are near-universal. Bodily heaviness, proprioceptive distortion, sound sensitivity, and spontaneous body sensations are prominent. Abnormal heartbeat from QTc prolongation (mean max 95 ms) requires continuous cardiac monitoring. Appetite suppression is pronounced.
Acute duration is 12–24 hours. Insomnia, physical fatigue, and heightened sensory sensitivity persist 24–72 hours. Mandatory cardiac monitoring with defibrillation access is required throughout.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Vestibular distortion · Depth perception distortion · Light sensitivity · Proprioceptive distortion · Sound sensitivity · Brightness alteration · Color alteration · Auditory distortion · Visual drifting · Visual haze / noise · Visual morphing · Synesthesia · Tracers · Internal hallucinations · External hallucinations · Perspective hallucinations · Auditory hallucinations · Shadow people
Sound sensitivity · Brightness alteration · Color alteration · Auditory distortion · Visual drifting · Visual haze / noise · Visual morphing · Synesthesia · Tracers · Internal hallucinations · External hallucinations · Perspective hallucinations · Auditory hallucinations · Shadow people
Dizziness · Physical fatigue · Nystagmus (eye wobbles) · Trembling · Vomiting · Involuntary body movements · Appetite suppression · Bodily heaviness · Body schema distortion · Excessive sweating · Heart rate perception changes · Restlessness · Spontaneous body sensations · Stimulation · Bodily pressures · Dry mouth · Headache · Muscle tension · Salivation · Tingling / electric sensations · Vibrations / buzzing · Pain suppression · Bodily dissociation
Vomiting · Involuntary body movements · Appetite suppression · Bodily heaviness · Body schema distortion · Excessive sweating · Heart rate perception changes · Restlessness · Spontaneous body sensations · Stimulation · Bodily pressures · Dry mouth · Headache · Muscle tension · Salivation · Tingling / electric sensations · Vibrations / buzzing · Pain suppression · Bodily dissociation
Cognitive fatigue · Confusion · Immersion enhancement · Focus suppression · Information processing suppression · Thought disorganization · Cognitive dysphoria · Memory fragmentation · Openness enhancement · Thought connectivity · Multiple thought streams · Thought loops · Delirium · Amnesia · Delusions
Focus suppression · Information processing suppression · Thought disorganization · Cognitive dysphoria · Memory fragmentation · Openness enhancement · Thought connectivity · Multiple thought streams · Thought loops · Amnesia · Delusions
Emotional lability · Simultaneous emotions · Empathy enhancement · Irritability · Euphoria
Euphoria
Emotional susceptibility · Sociability suppression · Disinhibition · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Boundary dissolution · Ego dissolution · Identity alteration
Transpersonal feelings · Transpersonal memory access · Entity contact · Near-death experience · Non-dual awareness
Non-dual awareness
Timeline · by preparation
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- —
Toxicity
Cardiac toxicity is the primary acute safety concern for all ibogaine-containing preparations. Ibogaine and noribogaine block the hERG potassium channel that governs cardiac repolarization.[21] In an open-label study of 14 opioid-dependent patients receiving 10 mg/kg ibogaine HCl, mean maximum QTc prolongation was 95 ms (range 29–146 ms), and 50% of subjects exceeded QTc 500 ms.[9] In 6 of 14 subjects, QTc remained above 450 ms beyond 24 hours post-administration.[9]
Fatal cardiac arrhythmias have been reported, with deaths occurring predominantly in unsupervised settings without continuous cardiac monitoring.[11][28] The UK National Poisons Information Service documents real-world ibogaine toxicity presentations over a 10-year case series.[29] Because noribogaine's half-life extends to 28–48 hours, cardiac risk persists well beyond the visionary phase — sudden death has been reported up to 72 hours after ingestion.[11][21]
Neurotoxicity: In rats, ibogaine causes indirect excitotoxic degeneration of Purkinje cells in the cerebellar vermis at high doses.[30][31] At 40 mg/kg — within the anti-addictive dose range in rodents — this effect was not observed,[32] suggesting anti-addictive and neurotoxic thresholds may be separable. In humans, severe transient ataxia was observed in all 14 patients in a clinical safety study.[9] Long-term Purkinje cell effects in humans at therapeutic doses have not been established; the MISTIC cohort showed structural brain improvements rather than deterioration at one month.[27]
Contaminant and adulterant risk: Commercial iboga products present significant quality concerns. GC/MS analysis of 16 products found unknown substances in almost all samples, and one product labeled as "iboga" contained no detectable iboga alkaloids.[12] No published analytical data on heavy metal contamination (lead, cadmium, arsenic, mercury), pesticide residues, or mycotoxin levels in commercial iboga products were identified. safety citation needed Unlike regulated cannabis markets, no jurisdiction mandates ISO/IEC-accredited laboratory testing or Certificate of Analysis requirements for iboga products. Independent analytical verification before use is the only available risk mitigation for product quality.[12]
Psychological Risks
Challenging and dysphoric experiences are a documented component, identified as one of seven empirically-derived factors ("Discomfort and challenge") in the Ibogaine Experience Scale (N=499).[7] Anxiety, fear, confrontation with difficult autobiographical material, and nausea-related distress are commonly reported during the acute phase.[33]
Risk of acute psychological decompensation exists in individuals with pre-existing psychotic spectrum disorders. Delirium-like states may occur at high doses, and hyperekplexia (exaggerated startle response) has been reported during the residual phase. No prevalence estimates for ibogaine-associated acute psychosis have been published.
safety citation needed Long-term psychological risks of ibogaine in the general population remain uncharacterized beyond case reports and observational cohorts.
Tolerance & Dependence
Ibogaine does not produce classical pharmacological tolerance. It is typically administered as a single dose in therapeutic contexts, and no published evidence documents dose escalation or tolerance development.[34][20]
Ibogaine does not appear to produce physical dependence. No withdrawal has been documented in humans. Traditional Bwiti ceremonial use is intermittent (initiation rites, periodic ceremonies), not daily. Animal self-administration models do not show ibogaine self-administration, and no compulsive redosing patterns have been observed.[10]
Abuse liability is considered negligible. The experience is typically described as challenging and physically demanding rather than recreationally reinforcing.
Drug Interactions
CYP2D6 inhibitors represent the most clinically significant herb-drug interaction. Co-administration of any potent CYP2D6 inhibitor (paroxetine, fluoxetine, bupropion, quinidine) approximately doubles the combined active moiety (ibogaine + noribogaine) exposure and proportionally increases cardiac risk.[8]
QT-prolonging agents compound ibogaine's hERG blockade. Co-administration with methadone, tricyclic antidepressants, antipsychotics, certain SSRIs, or some antihistamines elevates risk of torsades de pointes.[11][28]
Opioid interactions are complex and timing-dependent. Ibogaine may precipitate opioid withdrawal or attenuate it depending on the timing relative to last opioid dose.[20][35] Discontinuation of methadone or buprenorphine for ibogaine treatment creates a dual hazard: incomplete tapering risks precipitated withdrawal, while post-ibogaine loss of opioid tolerance increases overdose risk.[36]
Serotonergic agents: Ibogaine's SERT inhibition creates a theoretical serotonin syndrome risk when combined with MAOIs or serotonin releasers.[1] safety citation needed No published clinical case report of ibogaine-induced serotonin syndrome was identified.
Contraindications
Pre-existing cardiac conditions constitute an absolute contraindication. Any history of QT prolongation, cardiac arrhythmia, structural heart disease, or heart failure precludes ibogaine administration.[21][9]
CYP2D6 poor metabolizer genotype is a major risk factor. These individuals experience approximately double the active moiety exposure, substantially increasing cardiac and neurological risk.[8][28] CYP2D6 genotyping is recommended before any ibogaine administration.
Concurrent QT-prolonging medications must be discontinued with appropriate washout periods. This includes methadone, many antipsychotics, tricyclic antidepressants, and certain antibiotics (macrolides, fluoroquinolones).
Severe hepatic impairment compromises CYP-mediated ibogaine metabolism, potentially resulting in unpredictable drug exposure.
Personal or family history of psychotic spectrum disorders (schizophrenia, schizoaffective disorder) constitutes a relative contraindication due to risk of precipitated psychosis.[37]
Pregnancy is an absolute contraindication. No reproductive safety data have been published.
Active opioid maintenance therapy without supervised tapering creates a dual risk: precipitated withdrawal during ibogaine treatment and post-treatment overdose from reduced tolerance.[36]
Electrolyte abnormalities — particularly hypokalemia and hypomagnesemia — potentiate QT prolongation and must be corrected before ibogaine administration.[37]
Preparations[edit]
Raw root bark (oral)
The traditional preparation is dried inner root bark, consumed by chewing or swallowing as shavings or coarse powder. Ibogaine content ranges from 0.6% to 11.2% of dry weight,[12] making dose prediction from uncharacterized bark impossible. Traditional Bwiti initiation doses involve consumption of root bark over 1–3 days in quantities reported as several hundred grams.[13] Onset is gradual (1–3 hours), with the acute visionary phase lasting 12–24 hours and residual effects persisting up to 72 hours. Nausea and vomiting are near-universal with raw bark due to the volume of plant material required and the presence of the full alkaloid spectrum. The taste is intensely bitter.
Total alkaloid extract (oral)
Total alkaloid extract (sometimes labeled "TA") is a semi-purified preparation that concentrates the full alkaloid spectrum of the root bark, typically reported at roughly 15–35% total alkaloid content by weight. TA delivers a pharmacological profile closer to whole root bark than to purified ibogaine HCl, retaining the minor co-alkaloids (tabernanthine, ibogamine, voacangine). Doses are substantially lower by weight than raw bark due to concentration, but the same variability problem applies — alkaloid ratios and total potency differ between batches. Onset, duration, and effect character resemble root bark, with somewhat reduced gastrointestinal distress due to lower material volume.
Purified ibogaine HCl (oral)
Ibogaine hydrochloride is the pharmaceutical-grade preparation used in most clinical and clinic settings. It delivers a single pharmacokinetically defined compound, eliminating the variability introduced by minor co-alkaloids and batch inconsistency. Clinical studies have used doses in the range of 10–20 mg/kg.[9][8] Onset occurs at approximately 1.5–4 hours post-ingestion,[8][38] with the acute phase lasting 12–24 hours. Cardiac risk (QTc prolongation) is present with purified ibogaine HCl and requires continuous monitoring.[9] The experience tends to be described as "cleaner" than raw bark, with less gastrointestinal distress but equivalent visionary intensity at equivalent ibogaine doses.
Magnesium-ibogaine combination
The MISTIC trial protocol co-administered magnesium with ibogaine in a supervised clinical setting.[5] The rationale for magnesium co-administration includes its role as a natural hERG channel modulator and potential cardioprotective effect, though this specific combination has not been independently validated in controlled cardiac safety studies.
Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.
Harm Reduction[edit]
Forms & Identification
Iboga preparations vary enormously in potency and purity. Raw root bark, total alkaloid extracts, and purified ibogaine HCl are pharmacologically distinct products with non-overlapping dose ranges. GC/MS analysis of commercial products found unknown adulterants in almost all samples tested, and one product labeled "iboga" contained no iboga alkaloids at all.[12]
No jurisdiction currently mandates ISO/IEC-accredited laboratory testing or Certificate of Analysis requirements for iboga products. Independent analytical verification by GC/MS or HPLC is the only reliable way to confirm identity, purity, and alkaloid concentration before use. For purified ibogaine HCl, a Certificate of Analysis from the supplier specifying ibogaine content and absence of voacangine (which adds cardiac risk) is the minimum standard. For raw root bark or total alkaloid extract, assume extreme batch-to-batch variability and treat every new batch as an unknown quantity.
Guidelines
- Cardiac screening is non-negotiable. A baseline 12-lead ECG with QTc measurement must be obtained before any ibogaine administration. Individuals with QTc above 450 ms, any history of arrhythmia, or structural heart disease should not proceed.[21][9]
- CYP2D6 genotyping should be completed before administration. Poor metabolizers face approximately double the active moiety exposure.[8]
- Discontinue all CYP2D6 inhibitors and QT-prolonging medications with appropriate washout periods before any ibogaine session. This includes paroxetine, fluoxetine, bupropion, methadone, tricyclic antidepressants, and many antipsychotics.
- Correct electrolyte imbalances — particularly potassium and magnesium — before administration.[37]
- Continuous cardiac monitoring (telemetry or repeated 12-lead ECGs) should be maintained for at least 24 hours post-administration and ideally through 72 hours, given noribogaine's prolonged half-life.
- Start with the lowest effective preparation. If using root bark or total alkaloid extract, begin with a small test dose and wait at least 2 hours before any additional consumption. Never estimate dose from uncharacterized bark.
- Hydration and nutrition: Maintain IV or oral hydration access. Nausea and vomiting are near-universal; anti-emetics should be available.
- Opioid tapering: If discontinuing opioid maintenance therapy for ibogaine treatment, complete the taper under medical supervision. Incomplete tapering risks precipitated withdrawal; post-ibogaine loss of opioid tolerance increases overdose risk on resumption.[36]
Set & Setting
Ibogaine sessions are not recreational events. The experience lasts 12–24 hours in acute phase with residual effects to 72 hours, involves near-total physical incapacitation, and frequently surfaces difficult psychological material. A supervised clinical or ceremonial setting with continuous cardiac monitoring is the minimum safe environment.
The session space should be quiet, dimly lit, and free from sudden stimuli — hyperekplexia (exaggerated startle response) is reported during the residual phase. A sitter or medical attendant must be present for the entire acute phase and should remain available through the 72-hour cardiac risk window. Ambulatory movement without assistance is unsafe during the acute phase due to severe ataxia.[9]
Aftercare & integration. The ibogaine afterglow period extends 24–72 hours beyond the acute visionary phase. During this window, noribogaine continues to exert pharmacological activity, and cardiac monitoring should be maintained.
Physical recovery priorities include rehydration (oral fluids or IV if vomiting was severe), gentle reintroduction of food, and rest. Ataxia and physical weakness may persist for 24–48 hours after the visionary phase resolves. Avoid driving, operating machinery, or any activity requiring coordination during this period.
Psychological integration is widely considered a critical component of therapeutic ibogaine use. The visionary content is often dense, emotionally charged, and autobiographical. Structured integration sessions with a trained therapist or experienced facilitator — beginning 1–3 days after the session and continuing over subsequent weeks — help process the material and translate insights into sustained behavioral change.
Recovery & Support
Ibogaine itself does not produce dependence or a withdrawal syndrome. Recovery support in the ibogaine context typically addresses the underlying condition that motivated treatment — most commonly opioid use disorder, alcohol use disorder, or trauma-related conditions.
Post-ibogaine opioid safety: Individuals who used ibogaine to interrupt opioid dependence face a critical risk period. Opioid tolerance is substantially reduced after ibogaine treatment, and resumption of pre-treatment opioid doses can be fatal.[36] Ongoing addiction medicine support, including consideration of maintenance therapy, should be arranged before the ibogaine session.
Resources:
- SAMHSA National Helpline: 1-800-662-4357 (US, free, confidential, 24/7)
- Global Ibogaine Therapy Alliance (GITA): provider directory and safety information
- Crisis Text Line: text HOME to 741741 (US)
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Irregular heartbeat, chest pain, or palpitations during or after an ibogaine session
- Loss of consciousness or unresponsiveness
- Seizure activity
- Breathing difficulty or cessation
- Severe confusion or psychotic symptoms persisting beyond the expected acute phase
Immediate steps:
- 1. Call emergency services immediately if cardiac symptoms, loss of consciousness, or breathing difficulty occur.
- 2. Place an unresponsive person in the recovery position.
- 3. Do not leave the person alone — cardiac events can occur up to 72 hours post-ingestion.
- 4. If available, attach an AED (automated external defibrillator) and follow its prompts.
- 5. Monitor breathing and pulse continuously until paramedics arrive.
What to tell the dispatcher:
- The person took ibogaine (spell it out: I-B-O-G-A-I-N-E)
- Approximate dose and preparation type (root bark, extract, or ibogaine HCl) if known
- Time of ingestion
- Current symptoms, especially any cardiac irregularity
- Note: Good Samaritan laws exist in many jurisdictions and provide legal protection for reporting drug-related emergencies
Reversal agents: No specific reversal agent for ibogaine exists. Treatment is supportive: cardiac monitoring, electrolyte correction, and management of arrhythmias per standard ACLS protocols. The prolonged half-life of noribogaine means monitoring must continue well beyond symptom resolution.
Legal Status[edit]
Ibogaine is not listed in any of the three UN drug convention schedules (1961, 1971, 1988), so national laws govern independently. The result is a fragmented international landscape: ibogaine is a Schedule I controlled substance in the United States at the federal level, yet legal or unregulated in several countries where treatment clinics operate openly. A 2026 US executive order directed accelerated regulatory review,[6] and nine US states have enacted ibogaine-related legislation as of May 2026,[18] making the legal environment unusually dynamic.
| Jurisdiction | Status | Notes |
|---|---|---|
| United States (federal) | Schedule I | Classified under the Controlled Substances Act since 1967. No accepted medical use at federal level. A 2026 executive order directed FDA and DEA to accelerate research and create Right to Try pathways.[6] |
| United States (state level) | Varies | Nine states enacted ibogaine-related legislation as of May 2026, including Texas ($50M clinical research), Kentucky ($21M/year SUD research), Oregon (first regulated ibogaine program), and Louisiana (psychedelic-assisted therapy program). Nine additional states have active bills.[18] |
| Mexico | Unscheduled | Physician-supervised administration is lawful. Most international ibogaine treatment clinics operate in Mexico.[39] |
| Brazil | Licensed medical use | Licensed clinics operate under ANVISA oversight.[39] |
| New Zealand | Class C controlled drug | Prescription required for lawful possession or use.[39] |
| Netherlands | Not prohibited | Therapeutic use permitted; several licensed clinics operate.[39] |
| South Africa | Medical supervision required | Not specifically prohibited; medical oversight required for administration.[39] |
| Costa Rica | Unregulated | No specific prohibition; ibogaine treatment openly practiced.[39] |
| United Kingdom | Controlled substance | Not licensed for medical use. NPIS monitors toxicity cases.[29] citation needed Exact Misuse of Drugs Act schedule placement requires verification. |
| Gabon | National heritage plant | Declared "national cultural heritage strategic reserve" in 2000. Wild harvest export banned in 2019. Cultivation permitted with Ministry approval.[17] |
| European Union | Varies by member state | No EU-wide scheduling. Generally not approved for medical use in most member states. citation needed Member-state-level scheduling requires jurisdiction-specific verification. |
| Australia | Controlled | citation needed Specific TGA scheduling and state-level provisions require verification. |
Treaty and analog considerations
Because ibogaine is absent from all three UN drug convention schedules, nations are under no treaty obligation to control T. iboga or ibogaine. This regulatory gap explains why countries such as Mexico, Brazil, and the Netherlands permit ibogaine use without violating international commitments. The plant T. iboga itself carries additional legal complexity in Gabon, where it is protected as cultural heritage irrespective of drug scheduling.
safety citation needed US legal status is rapidly evolving. The 2026 executive order and multiple state-level bills may substantially alter ibogaine's regulatory status before the next scheduled review of this article.
references
- [1]
- [2]
- [3] ^abcQuiroz D, van Andel T (2018) The Cultural Importance of Plants in Western African Religions — Economic Botany doi:10.1007/s12231-018-9410-x
- [4] ^abRodríguez-Cano BJ et al., Bouso JC (2023) Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiences — Drug and alcohol review doi:10.1111/dar.13587
- [5] ^abcCherian KN, Keynan JN, Anker L, et al. (2024) Magnesium-ibogaine therapy in veterans with traumatic brain injuries — Nature medicine doi:10.1038/s41591-023-02705-w
- [6] ^abcdKozlov M (2026) US speeds up research into mind-altering drugs - including mysterious 'ibogaine' — Nature doi:10.1038/d41586-026-01286-1